GSK to skip regulatory submissions for experimental arthritis drug

Content of the article

British drugmaker GSK said on Thursday it would not proceed with regulatory submissions for its investigational treatment for moderate to severe rheumatoid arthritis (RA) after the drug failed to meet a key target in a study.

In a late-stage study, the antibody drug otilimab did not make a significant difference in improving joint swelling and tenderness for easier movement in patients who don’t had not responded to other forms of treatment before.

Content of the article

« The limited efficacy demonstrated does not support an appropriate benefit/risk profile for otilimab as a potential treatment for rheumatoid arthritis, » the company said in a statement. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Sherry Jacob-Phillips)